• 
  Marcela Carausu, Matthieu Carton, Luc Cabel, Anne Patsouris, Christelle Levy, et al.. Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database. Therapeutic Advances in Medical Oncology, 2022, 14, pp.175883592210770. ⟨10.1177/17588359221077082⟩. ⟨hal-03867853⟩
• 
  Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, et al.. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.. Lancet Oncology, 2022, Lancet Oncology, 23 (8), pp.1044-1054. ⟨10.1016/S1470-2045(22)00380-1⟩. ⟨hal-04387055⟩
• 
  Hélène Tubeuf, Sandrine M Caputo, Teresa Sullivan, Julie Rondeaux, Sophie Krieger, et al.. Calibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by Using BRCA2 Exon 3 as a Model System. Cancer Research, 2020, 80 (17), pp.3593-3605. ⟨10.1158/0008-5472.CAN-20-0895⟩. ⟨hal-03597164⟩
• 
  Aurélien Haustrate, Clément Cordier, George Shapovalov, Adriana Mihalache, Emilie Desruelles, et al.. Trpv6 channel targeting using monoclonal antibody induces prostate cancer cell apoptosis and tumor regression. Cell Death and Disease, 2024, 15 (6), pp.419. ⟨10.1038/s41419-024-06809-0⟩. ⟨hal-04665305⟩
• 
  Victorine Trentesaux, Sophie Maiezza, Emilie Bogart, Marie-Cécile Le Deley, Emmanuel Meyer, et al.. Stereotactic body radiotherapy as a viable treatment on extracranial oligometastases in melanoma patients: a retrospective multicentric study. Frontiers in Oncology, 2024, 14, pp.1322515. ⟨10.3389/fonc.2024.1322515⟩. ⟨inserm-04659931⟩
• 
  Abel Cordoba, Estelle Gesta, Alexandre Escande, Alexandra Noeuveglise, Romain Cayez, et al.. Interstitial needles versus intracavitary applicators only for locally advanced cervical cancer: results from real-life dosimetric comparisons. Frontiers in Oncology, 2024, 14, pp.1347727. ⟨10.3389/fonc.2024.1347727⟩. ⟨inserm-04659922⟩
• 
  Julien Guérin, Amine Nahid, Louis Tassy, Marc Deloger, François Bocquet, et al.. Consore: A Powerful Federated Data Mining Tool Driving a French Research Network to Accelerate Cancer Research. International Journal of Environmental Research and Public Health, 2024, 21 (2), pp.189. ⟨10.3390/ijerph21020189⟩. ⟨inserm-04659888⟩
• 
  J.Y. Blay, N. Penel, T. Valentin, P. Anract, F. Duffaud, et al.. Improved nationwide survival of sarcoma patients with a network of reference centers. Annals of Oncology, 2024, 35 (4), pp.351-363. ⟨10.1016/j.annonc.2024.01.001⟩. ⟨inserm-04658953⟩
• 
  Nicolas André, Marie Cécile Le Deley, Clémence Léguillette, Alicia Probst, Leen Willems, et al.. METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumors. European Journal of Cancer, 2024, 198, pp.113525. ⟨10.1016/j.ejca.2024.113525⟩. ⟨hal-04653328⟩
• 
  Davide Soldato, Stefan Michiels, Julie Havas, Antonio Di Meglio, Martina Pagliuca, et al.. Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast Cancer. Journal of Clinical Oncology, 2024, pp.JCO2301959. ⟨10.1200/jco.23.01959⟩. ⟨inserm-04639986⟩
• 
  Jeremie Naffrichoux, Pierre Poupin, William Pouillot, Claude Linassier, Nathalie Rioux-Leclercq, et al.. PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort. European Journal of Cancer, 2024, 205, pp.114121. ⟨10.1016/j.ejca.2024.114121⟩. ⟨hal-04615732⟩
• 
  Charles de Marcellus, Arnault Tauziède-Espariat, Aurélie Cuinet, Claudia Pasqualini, Matthieu Robert, et al.. The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients. Journal of Neuro-Oncology, 2022, 157 (2), pp.355-364. ⟨10.1007/s11060-022-03970-4⟩. ⟨hal-03674693⟩
• 
  Antonio Di Meglio, Elise Martin, Tracy E Crane, Cecile Charles, Aude Barbier, et al.. A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design. Trials, 2022, 23 (1), pp.193. ⟨10.1186/s13063-022-06090-6⟩. ⟨inserm-04614681⟩
• 
  Marie Lange, Sophie Lefevre Arbogast, Isabelle Hardy-Léger, Olivier Rigal, Johan Le Fel, et al.. Cognitive change in breast cancer patients up to 2 years after diagnosis. JNCI: Journal of the National Cancer Institute, 2022, 115 (3), pp.322-331. ⟨10.1093/jnci/djac240⟩. ⟨hal-03992251⟩
• 
  Pascale Varlet, Gwénaël Le Teuff, Marie-Cécile Le Deley, Felice Giangaspero, Christine Haberler, et al.. WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial. Neuro-Oncology, 2020, 22 (1), pp.116-127. ⟨10.1093/neuonc/noz142⟩. ⟨hal-04515905⟩
• 
  Camille Winnicki, Pierre Leblond, Franck Bourdeaut, Anne Pagnier, Gilles Paluenzela, et al.. Retrospective National “Real Life” Experience of the SFCE with the Metronomic MEMMAT and MEMMAT-like Protocol. Journal of Clinical Medicine, 2023, 12 (4), pp.1415. ⟨10.3390/jcm12041415⟩. ⟨hal-04593818⟩
• 
  P. Kubicek, A. L. Cesne, C. Lervat, M. Toulmonde, C. Chevreau, et al.. Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC.. BMC Cancer, 2023, BMC Cancer, 23 (1), pp.69. ⟨10.1186/s12885-023-10556-4⟩. ⟨hal-04315885⟩
• 
  Susanne A Gatz, Anne C Harttrampf, Caroline Brard, Francisco Bautista, Nicolas André, et al.. Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial. Clinical Cancer Research, 2023, 30 (4), pp.741 - 753. ⟨10.1158/1078-0432.ccr-23-2959⟩. ⟨inserm-04590103⟩
• 
  Gilles Houvenaeghel, Alexandre De Nonneville, Monique Cohen, Jean-Marc Classe, Fabien Reyal, et al.. Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study. European Journal of Cancer, 2022, 176, pp.58-69. ⟨10.1016/j.ejca.2022.08.027⟩. ⟨hal-04084967⟩
• 
  Gilles Freyer, Anne Floquet, Olivier Trédan, Aurore Carrot, Carole Langlois-Jacques, et al.. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature Communications, 2024, 15 (1), pp.1985. ⟨10.1038/s41467-024-45974-w⟩. ⟨hal-04549309⟩

184

238